Histone deacetylase inhibitor based prodrugs
Publication type: Journal Article
Publication date: 2020-10-01
scimago Q1
wos Q1
SJR: 1.142
CiteScore: 11.3
Impact factor: 5.9
ISSN: 02235234, 17683254
PubMed ID:
32679451
Organic Chemistry
Drug Discovery
General Medicine
Pharmacology
Abstract
Histone deacetylases (HDACs) are a family of enzymes which play important roles in the development and progression of cancers. Inhibition of HDACs has been widely studied as a therapeutic strategy in the discovery of anticancer drugs. HDAC inhibitors (HDACIs) have exhibited potency against a variety of cancer types, and four of them have been approved by the US FDA for cancer treatment. However, the clinical benefits of current HDACIs is limited by the insufficient physicochemical property, selectivity and potency. To improve the clinical potential of HDACIs, the prodrug strategy had been utilized to improve the in vivo pharmacokinetic and pharmacodynamic performances of HDACIs. Enhancements in the stability, water solubility, lipophilicity, oral bioavailability and tumor cell selectivity were reported by various studies. Herein, the development of different kinds of HDACI-based prodrug is summarized for the further structural modification of HDACIs with high potential to be drug candidates.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
International Journal of Molecular Sciences
3 publications, 8.57%
|
|
|
Bioorganic Chemistry
2 publications, 5.71%
|
|
|
Molecular Pharmaceutics
2 publications, 5.71%
|
|
|
Onco Therapeutics
1 publication, 2.86%
|
|
|
Bulletin of the Chemical Society of Japan
1 publication, 2.86%
|
|
|
Pharmaceuticals
1 publication, 2.86%
|
|
|
Molecular Neurobiology
1 publication, 2.86%
|
|
|
Frontiers in Cell and Developmental Biology
1 publication, 2.86%
|
|
|
Frontiers in Oncology
1 publication, 2.86%
|
|
|
Frontiers in Endocrinology
1 publication, 2.86%
|
|
|
International Journal of Pharmaceutics
1 publication, 2.86%
|
|
|
Bioorganic and Medicinal Chemistry
1 publication, 2.86%
|
|
|
Chemical Communications
1 publication, 2.86%
|
|
|
Journal of Neurophysiology
1 publication, 2.86%
|
|
|
Clinical Epigenetics
1 publication, 2.86%
|
|
|
European Journal of Medicinal Chemistry
1 publication, 2.86%
|
|
|
Archiv der Pharmazie
1 publication, 2.86%
|
|
|
Experimental Hematology and Oncology
1 publication, 2.86%
|
|
|
Environmental Toxicology and Pharmacology
1 publication, 2.86%
|
|
|
Chemical Biology and Drug Design
1 publication, 2.86%
|
|
|
Medicinal Chemistry Research
1 publication, 2.86%
|
|
|
Therapeutic Advances in Hematology
1 publication, 2.86%
|
|
|
Scientific Reports
1 publication, 2.86%
|
|
|
European Journal of Medical Research
1 publication, 2.86%
|
|
|
Communications Biology
1 publication, 2.86%
|
|
|
Cancer and Metastasis Reviews
1 publication, 2.86%
|
|
|
Journal of Orthopaedic Translation
1 publication, 2.86%
|
|
|
Signal Transduction and Targeted Therapy
1 publication, 2.86%
|
|
|
Materials Today Bio
1 publication, 2.86%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
7
8
9
|
|
|
Springer Nature
9 publications, 25.71%
|
|
|
Elsevier
9 publications, 25.71%
|
|
|
MDPI
4 publications, 11.43%
|
|
|
Frontiers Media S.A.
3 publications, 8.57%
|
|
|
American Chemical Society (ACS)
2 publications, 5.71%
|
|
|
Wiley
2 publications, 5.71%
|
|
|
Begell House
1 publication, 2.86%
|
|
|
Oxford University Press
1 publication, 2.86%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 2.86%
|
|
|
American Physiological Society
1 publication, 2.86%
|
|
|
IntechOpen
1 publication, 2.86%
|
|
|
SAGE
1 publication, 2.86%
|
|
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
35
Total citations:
35
Citations from 2024:
12
(34.29%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Fan W. et al. Histone deacetylase inhibitor based prodrugs // European Journal of Medicinal Chemistry. 2020. Vol. 203. p. 112628.
GOST all authors (up to 50)
Copy
Fan W., Zhang L., Jiang Q., Song W., Yan F., Zhang L. Histone deacetylase inhibitor based prodrugs // European Journal of Medicinal Chemistry. 2020. Vol. 203. p. 112628.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.ejmech.2020.112628
UR - https://doi.org/10.1016/j.ejmech.2020.112628
TI - Histone deacetylase inhibitor based prodrugs
T2 - European Journal of Medicinal Chemistry
AU - Fan, Wenli
AU - Zhang, Lihui
AU - Jiang, Qixao
AU - Song, Weiguo
AU - Yan, Fang
AU - Zhang, Lei
PY - 2020
DA - 2020/10/01
PB - Elsevier
SP - 112628
VL - 203
PMID - 32679451
SN - 0223-5234
SN - 1768-3254
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Fan,
author = {Wenli Fan and Lihui Zhang and Qixao Jiang and Weiguo Song and Fang Yan and Lei Zhang},
title = {Histone deacetylase inhibitor based prodrugs},
journal = {European Journal of Medicinal Chemistry},
year = {2020},
volume = {203},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1016/j.ejmech.2020.112628},
pages = {112628},
doi = {10.1016/j.ejmech.2020.112628}
}